Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
5.10
+0.04 (0.79%)
At close: Jun 4, 2026
EGX:RMDA Cash Flow Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 318.98 | 298.46 | 387.37 | 244.86 | 245.68 | 181.09 |
Depreciation & Amortization | 93.19 | 92.23 | 83.43 | 72.88 | 65.48 | 46.18 |
Loss (Gain) From Sale of Assets | -1.13 | -0.15 | -0.01 | -0.14 | 0.13 | 0.72 |
Asset Writedown & Restructuring Costs | -0.38 | 2.56 | 2.51 | - | - | - |
Stock-Based Compensation | 31.84 | 15.95 | 16.29 | 17.77 | 17.85 | - |
Provision & Write-off of Bad Debts | 103.2 | 104.8 | 11.44 | 3.81 | 3.64 | 0.11 |
Other Operating Activities | 76.84 | 60.94 | 9.24 | 2.42 | -8.44 | -10.39 |
Change in Accounts Receivable | -982.13 | -741.17 | -218.62 | -374.86 | -243.64 | -29.45 |
Change in Inventory | 122.19 | -273.6 | -439.51 | 30.97 | -88.59 | 47.58 |
Change in Accounts Payable | 96.37 | 52.98 | 276.38 | 16.97 | 68.59 | 31.51 |
Change in Other Net Operating Assets | 72.95 | 343.33 | -435.45 | -59.17 | -31.35 | -25.99 |
Operating Cash Flow | -68.1 | -43.67 | -306.92 | -44.5 | 29.35 | 241.35 |
Operating Cash Flow Growth | - | - | - | - | -87.84% | - |
Capital Expenditures | -157.87 | -155.9 | -64.93 | -91.05 | -34.38 | -52.67 |
Sale of Property, Plant & Equipment | 2.04 | 0.2 | 1.72 | 0.18 | 0.02 | 0.02 |
Sale (Purchase) of Intangibles | -123.68 | -594.95 | -1.71 | -162.44 | -93.9 | -185.53 |
Investment in Securities | 77.01 | 237.39 | 120.66 | 194.68 | 167.47 | 68.06 |
Other Investing Activities | 35.57 | - | -93.84 | - | - | - |
Investing Cash Flow | -166.95 | -513.26 | -38.09 | -58.63 | 39.22 | -170.11 |
Short-Term Debt Issued | - | 3,434 | 1,998 | 1,421 | 1,205 | 1,172 |
Total Debt Issued | 3,201 | 3,434 | 1,998 | 1,421 | 1,205 | 1,172 |
Short-Term Debt Repaid | - | -2,681 | -1,551 | -1,265 | -1,121 | -1,156 |
Long-Term Debt Repaid | - | -13.25 | -6.34 | -5.74 | -27.14 | -71.19 |
Total Debt Repaid | -2,781 | -2,694 | -1,558 | -1,271 | -1,149 | -1,228 |
Net Debt Issued (Repaid) | 419.61 | 740.47 | 440.9 | 149.72 | 56.96 | -55.09 |
Issuance of Common Stock | 1.88 | 1.88 | 3.23 | 2.11 | - | - |
Repurchase of Common Stock | - | - | - | - | -65.93 | - |
Common Dividends Paid | -188.91 | -188.91 | -121.28 | -16.76 | -24.31 | -14.7 |
Financing Cash Flow | 232.58 | 553.44 | 322.86 | 135.07 | -33.28 | -69.79 |
Foreign Exchange Rate Adjustments | 5.5 | -24.82 | 34.48 | 0.42 | 17.22 | -0.19 |
Net Cash Flow | 3.04 | -28.32 | 12.32 | 32.37 | 52.51 | 1.26 |
Free Cash Flow | -225.98 | -199.57 | -371.85 | -135.54 | -5.03 | 188.68 |
Free Cash Flow Margin | -5.26% | -4.87% | -13.43% | -7.05% | -0.34% | 15.14% |
Free Cash Flow Per Share | -0.11 | -0.10 | -0.18 | -0.07 | -0.00 | 0.09 |
Cash Interest Paid | 513.94 | 526.8 | 294.66 | 186.52 | 84.82 | 89.41 |
Cash Income Tax Paid | 92.68 | 101.81 | 67.07 | 60.69 | 44.29 | 28.91 |
Levered Free Cash Flow | -331.76 | -834.46 | -552.55 | -381.77 | -108.98 | -7.86 |
Unlevered Free Cash Flow | -0.17 | -502.42 | -360.54 | -262.27 | -53.32 | 49.03 |
Change in Working Capital | -690.62 | -618.46 | -817.2 | -386.09 | -295 | 23.64 |